Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Zymeworks Inc | ZYME | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.98 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 6.015 - 13.14 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 8.98 | USD |
Zymeworks Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
453.75M | 70.57M | - | 76.3M | -118.67M | -1.68 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Zymeworks News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ZYME Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.37 | 9.6197 | 8.905 | 9.11 | 527,654 | -0.39 | -4.16% |
1 Month | 8.76 | 9.6197 | 7.97 | 8.88 | 699,488 | 0.22 | 2.51% |
3 Months | 12.52 | 13.14 | 7.97 | 9.86 | 651,788 | -3.54 | -28.27% |
6 Months | 8.29 | 13.14 | 7.97 | 10.12 | 561,751 | 0.69 | 8.32% |
1 Year | 9.80 | 13.14 | 6.015 | 8.93 | 528,559 | -0.82 | -8.37% |
3 Years | 6.38 | 13.14 | 6.015 | 8.79 | 623,951 | 2.60 | 40.75% |
5 Years | 6.38 | 13.14 | 6.015 | 8.79 | 623,951 | 2.60 | 40.75% |
Zymeworks Description
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |